ISOPTIN

This brand name is authorized in Austria, Australia, Canada, Cyprus, Germany, Estonia, Finland, Hong Kong, Ireland, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, South Africa

Active ingredients

The drug ISOPTIN contains one active pharmaceutical ingredient (API):

1 Verapamil
UNII V3888OEY5R - VERAPAMIL HYDROCHLORIDE

Verapamil is a phenylalkylamine calcium antagonist which blocks the inward movement of calcium ions in cardiac muscle cells, in smooth muscle cells of the coronary and systemic arteries and in cells of the intracardiac conduction system. It lowers heart rate, increases myocardial perfusion and reduces coronary spasm. Because of its effect on the movement of calcium in the intracardiac conduction system, verapamil reduces automaticity, decreases conduction velocity and increases the refractory period.

Read about Verapamil

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
ISOPTIN Solution for injection / infusion Health Products Regulatory Authority (IE) MPI, EU: SmPC
ISOPTIN Film‐coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C08DA01 Verapamil C Cardiovascular system → C08 Calcium channel blockers → C08D Selective calcium channel blockers with direct cardiac effects → C08DA Phenylalkylamine derivatives
Discover more medicines within C08DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 1241H, 1250T, 2208F
Country: CA Health Products and Food Branch Identifier(s): 00742554, 01907123, 01934317
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 00530896, 01284330, 01976772, 02459323, 02709406, 02709458, 02709464, 02791342, 03573825, 03573831
Country: EE Ravimiamet Identifier(s): 1017267, 1017278, 1073157, 1073180
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 508622, 559021
Country: HK Department of Health Drug Office Identifier(s): 01261, 26481
Country: IE Health Products Regulatory Authority Identifier(s): 29424, 29521, 29548, 38933, 39470
Country: IT Agenzia del Farmaco Identifier(s): 020609044, 020609069, 020609083
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1002853, 1002855, 1090534
Country: MT Medicines Authority Identifier(s): AA1187/01601, AA1187/01602, AA565/78701
Country: NL Z-Index G-Standaard, PRK Identifier(s): 26832, 34800, 35408
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 1665, 1666, 1667, 1669, 1670
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100010337, 100030363, 100031434, 100032391, 100426411, 100446632, 100449056, 100458000, 100463200
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W68848001
Country: SG Health Sciences Authority Identifier(s): 00344P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699548030420, 8699548031953, 8699548090806, 8699548090820, 8699548750793, 8699548755255, 8699548755262
Country: ZA Health Products Regulatory Authority Identifier(s): D/7.1.4/118, R/7.1.4/195, V/7.1/280

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.